SABIC Launches Portfolio of Antimicrobial Compounds at MD&M West to Help Customers Enhance Safety of Healthcare Applications

Published Feb 12, 2013

ANAHEIM, Calif., Feb. 12, 2013- According to a 2011 report by the World Health Organization, in 2002 in the United States alone approximately 99,000 deaths were linked to healthcare associated infections (HCAIs).1 Here at MD&M West (booth #1701), SABIC’s Innovative Plastics business today introduced powerful new tools to help medical device manufacturers reduce HCAIs among patients and clinicians. SABIC’s nine new antimicrobial compounds featuring silver technology have been tested for log reduction values – the level of microbes eliminated from a surface – according to the ISO 22196-2007 protocol. They comprise one of the broadest antimicrobial portfolios in the industry and offer distinct advantages over off-the-shelf antimicrobial concentrates combined with third-party resins.